Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Production Of NIR-On-Ranger Stent With SOX On Hold

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific is ramping up produciton of its NIR Primo coronary stent - also known as the NIR-On-Ranger without the SOX securing system - after temporarily ceasing production of the system with SOX due to a higher than anticipated balloon failure rate, the firm says.

You may also be interested in...

Boston Scientific Liberty Stent Groomed To Face Next-Gen Cobalt Competitors

Boston Scientific will enroll approximately 400 patients in an ongoing clinical trial to support a PMA supplement for the firm's Taxus Liberty stent platform

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts